EMP16

EMP16 has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Aug 6, 2025: “The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 Trial”.

Intervention

1 paper studies it2 findingsUpdated

See all 1 papers on EMP16

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 3 trials, 1 about aging, 1 with no results posted.

“EMP16 demonstrating greater improvement in fatty liver index and quality of life compared to Conv-O (p < 0.01)”
The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 TrialObesity (Silver Spring, Md.)2025doi:10.1002/oby.24369

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 3 trials, 1 about aging, 1 with no results posted
  • Funder: Empros Pharma
  • 2 of 2 findings with company ties
  • 3 of 3 trials sponsored by its developers
  • Human trial1

Studies in people

1 study gave EMP16 to people and measured what changed.

What changedDesignPeopleSource

up: Improves quality of lifegreater improvement than Conv-O

down: Decreases fatty liver indexgreater improvement than Conv-O

Randomized trial6 months240 peoplePatient cohortsObesity (Silver Spring, Md.), Aug 6, 2025

What did studies of EMP16 find?

2

Studies of EMP16 measured 2 outcomes: fatty liver index and quality of life.

Fatty liver index

downin humans1

1 study
  1. EMP16 decreases fatty liver index in humans (compared with conventional orlistat) (greater improvement than Conv-O).

    “EMP16 demonstrating greater improvement in fatty liver index and quality of life compared to Conv-O (p < 0.01)”

    Human trialcompared with conventional orlistatliver6 months

    The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 Trial

    Obesity (Silver Spring, Md.)

More on Fatty liver index

Quality of life

upin humans1

1 study
  1. EMP16 improves quality of life in humans (compared with conventional orlistat) (greater improvement than Conv-O).

    “EMP16 demonstrating greater improvement in fatty liver index and quality of life compared to Conv-O (p < 0.01)”

    Human trialcompared with conventional orlistat6 months

    The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 Trial

    Obesity (Silver Spring, Md.)

Has EMP16 been tested in people?

1 of 3 about aging

Yes: 1 trial in people have been published.

Latest